Effect of γ-crotonolactone in experimental models of generalized absence seizures
暂无分享,去创建一个
[1] O. C. Snead,et al. The γ-hydroxybutyrate model of absence seizures: correlation of regional brain levels of γ-hydroxybutyric acid and γ-butyrolactone with spike wave discharges , 1991, Neuropharmacology.
[2] O. Snead. The ontogeny of GABAergic enhancement of the gamma-hydroxybutyrate model of generalized absence seizures. , 1990, Epilepsia.
[3] O. Snead,et al. In vivo conversion of γ-aminobutyric acid and 1,4-butanediol to γ-hydroxybutyric acid in rat brain , 1989 .
[4] J. Ferrendelli,et al. Comparison of the Anticonvulsant Activities of Ethosuximide, Valproate, and a New Anticonvulsant, Thiobutyrolactone , 1989, Epilepsia.
[5] A. Depaulis,et al. Suppressive effects of intranigral injection of muscimol in three models of generalized non-convulsive epilepsy induced by chemical agents , 1989, Brain Research.
[6] O. Snead. gamma-Hydroxybutyrate model of generalized absence seizures: further characterization and comparison with other absence models. , 1988, Epilepsia.
[7] A. Depaulis,et al. Effects of gamma-hydroxybutyrate and gamma-butyrolactone derivatives on spontaneous generalized non-convulsive seizures in the rat , 1988, Neuropharmacology.
[8] D. Naritoku,et al. Effects of anticonvulsant and convulsant gamma-butyrolactones and thiobutyrolactones on GABA-mediated chloride uptake. , 1987, Biochemical pharmacology.
[9] P. Skolnick,et al. Alkyl-substituted γ-butyrolactones inhibit [35S]TBPS binding to a GABA linked chloride ionophore , 1984 .
[10] O. Snead,et al. Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. , 1984, Biochemical pharmacology.
[11] O. Snead. Ontogeny of gamma-hydroxybutyric acid. II. Electroencephalographic effects. , 1984, Brain research.
[12] A. Depaulis,et al. Enhancement of spike and wave discharges by GABAmimetic drugs in rats with spontaneous petit-mallike epilepsy , 1984, Neuroscience Letters.
[13] O. Snead,et al. Ontogeny of cortical and subcortical electroencephalographic events in unrestrained neonatal and infant rats , 1983, Experimental Neurology.
[14] W. Klunk,et al. Alkyl-substituted γ-butyrolactones as potential tools in the study and treatment of epilepsy , 1983 .
[15] C. Wermuth,et al. High affinity binding site for γ-hydroxybutyric acid in rat brain , 1982 .
[16] O. Snead,et al. Ontogeny of γ-hydroxybutyric acid. I. Regional concentration in developing rat, monkey and human brain , 1981 .
[17] Pegram Gv,et al. Antagonism of gamma-hydroxybutyric acid-induced frequency shifts in the cortical EEG of rats by dipropylacetate. , 1980 .
[18] P. Person,et al. Neonatal rat surgery: avoiding maternal cannibalism. , 1979, Science.
[19] R. Roth,et al. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. , 1978, The Journal of pharmacology and experimental therapeutics.
[20] J. Lettieri,et al. Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. , 1978, Research communications in chemical pathology and pharmacology.
[21] J. Lettieri,et al. Evaluation and development of gas chromatographic procedures for the determination of γ-hydroxybutyric acid and γ-butyrolactone in plasma , 1978 .
[22] R. Roth,et al. KINETICS OF IN VIVO CONVERSION OF γ‐[3H]AMINOBUTYRIC ACID TO γ‐[3H]HYDROXYBUTYRIC ACID BY RAT BRAIN 1, 2 , 1977 .
[23] R. Roth,et al. Metabolism of [1-14C]γ-hydroxybutyric acid by rat brain after intraventricular injection , 1975 .
[24] R. Roth. Formation and regional distribution of γ-hydroxybutyric acid in mammalian brain , 1970 .
[25] N. J. Giarman,et al. Conversion in vivo of γ-aminobutyric to γ-hydroxybutyric acid in the rat , 1969 .
[26] S. Siegel,et al. Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.
[27] F. Wilcoxon,et al. A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.